Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery


Blandine Laferrère, New York Obesity Research Center, Columbia University College of Physicians and Surgeons, St Luke’s Roosevelt Hospital, Room 1034 Babcock, 1111 Amsterdam Avenue, New York, NY 10025, USA.
Tel: +1 212 523 4643
Fax: +1 212 523 4830
Email: bbl14@columbia.edu


Background:  The aim of the present study was to determine the mechanisms underlying Type 2 diabetes remission after gastric bypass (GBP) surgery by characterizing the short- and long-term changes in hormonal determinants of blood glucose.

Methods:  Eleven morbidly obese women with diabetes were studied before and 1, 6, and 12 months after GBP; eight non-diabetic morbidly obese women were used as controls. The incretin effect was measured as the difference in insulin levels in response to oral glucose and to an isoglycemic intravenous challenge. Outcome measures were glucose, insulin, C-peptide, proinsulin, amylin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) levels and the incretin effect on insulin secretion.

Results:  The decrease in fasting glucose (r = 0.724) and insulin (r = 0.576) was associated with weight loss up to 12 months after GBP. In contrast, the blunted incretin effect (calculated at 22%) that improved at 1 month remained unchanged with further weight loss at 6 (52%) and 12 (52%) months. The blunted incretin (GLP-1 and GIP) levels, early phase insulin secretion, and other parameters of β-cell function (amylin, proinsulin/insulin) followed the same pattern, with rapid improvement at 1 month that remained unchanged at 1 year.

Conclusions:  The data suggest that weight loss and incretins may contribute independently to improved glucose levels in the first year after GBP surgery.